Background
Kawasaki disease (KD) is an acute self-limited vasculitis of childhood that leads to coronary artery abnormalities (CAA) in approximate 5% of treated cases [
1]. It is the leading cause of acquired heart disease in children younger than 5 years of age in Asian countries. According to a latest epidemiological study in Shanghai, China, the average annual incidence rate of KD was 50.5 per 100,000 children during the period of 2008–2012 [
2]. In light of the 2017 American Heart Association (AHA) guidelines, the diagnosis criteria of KD include fever ≥5 days and four or more of the five major clinical features. Besides, incomplete KD should be considered in any case with persistent unexplained fever, fewer than 4 of the major clinical features, and compatible laboratory or echocardiographic findings [
3]. Elevation of acute-phase reactants such as erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) is nearly universal and very helpful to reflect disease severity. Song et al. [
4] evaluated the diagnostic efficiency of ESR and CRP in 67 children with persistent fever and found that the estimated sensitivity of ESR for predicting KD was 93.9%, and specificity was 83.3%; the estimated sensitivity of CRP for predicting KD was 69.0%, and specificity was 72.7%. Echocardiography is the primary imaging modality for cardiac assessment because it is noninvasive and has a very high sensitivity (100%) and specificity (95–100%) for the detection of abnormalities of the proximal coronary artery segments [
5].
Intravenous immunoglobulin (IVIG) combined with high-dose aspirin is the first choice for suppressing systemic inflammation and preventing CAA. In our latest study, white blood cells counts (WBC), absolute neutrophil counts (ANC), CRP and procalcitonin (PCT) levels markedly increased in the acute episode of KD, whereas declined to 30%~ 90% after IVIG treatment [
1]. On the other hand, a multi-center, randomized trial from USA documented that timely initiation of IVIG treatment could reduce the incidence of CAA from 20 to 6.8% at the two-week visit [
6]. Nevertheless, patients with a delayed diagnosis may still be candidates for IVIG treatment. Qiu et al. [
7] analyzed inflammatory mediators and risk factors for CAA in 59 KD children who received IVIG treatment > 10 days and found that a delayed IVIG treatment may contribute to the higher levels of CRP and ESR, and serve as an independent risk factor for the development of CAA (adjusted OR = 2.90, 95%CI = 1.42, 5.91). Despite IVIG plus high-dose aspirin is considered as the first-line treatment, some KD patients develop recrudescent or persistent fever more than 36 h after the end of IVIG infusion and are termed IVIG non-response [
3]. In this condition, another 2 g/kg dose of IVIG plus a corticosteroid is usually advocated [
8].
Several previous epidemiologic surveys have suggested the onset of incomplete KD experiences an increasing trend in China. A long-term retrospective study from Inner Mongolia revealed that the incidence of incomplete KD increased from 10.38% in 2003 to 40.12% in 2012 [
9]. In the last decade, the incidence of IVIG non-response ranged from 4.9 to 17.8% [
2,
10,
11]. Based on several epidemiological surveys from mainland China, the overall trend in CAA occurrence also appeared to be on the rise from 15.9 to 63.3%, far higher than the other Asian countries [
2,
12,
13]. Several published scoring systems have revealed that age in months, CRP and ESR were associated with incomplete KD; day of illness at initial treatment, age in months, percentage of neutrophils, platelet count (PLT), serum aspartate aminotransferase, sodium and CRP served as independent predictors of IVIG non-response; male, fever duration, albumin, percentage of eosionphils and monocytes predicted CAA risks [
11,
14‐
16]. In addition, the enhancement of pediatricians’ awareness may raise the diagnostic rate of incomplete KD and stimulate more aggressive initial therapy in the acute episode of KD. Given this background, we hypothesize that the time option of IVIG treatment should be in parallel with peak time of systemic inflammation; either earlier or later IVIG treatment may affect the clinical classification, therapeutic responsiveness and CAA occurrence in KD patients. Therefore, the major objective of the present study is to identify whether the time option of IVIG treatment could be associated with the clinical classification, therapeutic responsiveness and CAA occurrence in the acute episode of KD.
Discussion
IVIG is a well-established standard therapy for KD and effectively reduces systemic inflammation [
3]. Furthermore, IVIG treatment is effective in shortening the length of hospital stay and preventing undesirable cardiac events in KD patients. Klassen et al. [
18] compared the length of hospital stay and cost effectiveness in 100 KD patients with different treatment strategies, and discovered that the hospitalization time (3 days) was significantly shorter and the total medical expense ($118,200) was significantly lower in the IVIG high-dose group than those in the aspirin alone group (10 days and $323,400). In another retrospective study, Bal et al. [
19] identified the risks for development and delay in resolution of CAA in association with IVIG administration within or after 10 days of KD onset. The risk for CAA was significantly lower among these patients admitted within 10 days (OR = 3.1) in comparison with their counterparts received IVIG after 10 days (OR = 5.3); and the resolution time of CAA was significantly shorter among these patients admitted within 10 days than their counterparts (6 months vs.12 months). In the present study, we observed that the duration of fever decreased dramatically after the initial IVIG treatment in 142 KD patients, which was mainly attributed to the depressed systemic inflammation. Besides, the potential mechanisms of IVIG treatment may include several immunoregulative processes. Lau et al. [
20] established a murine model of KD to examine the effect of IVIG, and showed that IVIG inhibited T cell proliferation, tumor necrosis factor-α production and nuclear factor (NF) -κB activation in a dose-dependent manner, all of which are critical steps preventing coronary artery damage.
Although IVIG is highly effective in KD, approximately 10 to 20% of KD patients develop recrudescent or persistent fever at least 36 h after the end of their IVIG infusion [
21]. To date, the immunologic basis of IVIG non-response remains unknown. Several studies have documented that the single-nucleotide polymorphisms in STX1B and carcinoembryonic antigen-related cell adhesion molecule 1 play a vital role in IVIG non-response [
22,
23]. In the present study, 11 KD patients resisted to IVIG treatment and 7 of them (63.60%) received the initial IVIG dose on day 5 and 6. Similarly, a multi-institutional, retrospective cohort study from Japan indicated that the early treatment group (on day 4) had a significantly higher rate of IVIG non-response than the conventional treatment group [
24]. Therefore, earlier intervention before peak time of systemic inflammation may contribute to IVIG non-reponse.
As outlined in the 2017 AHA guidelines [
3], KD is accompanied by the gradual elevations of WBC, ANC, CRP and ESR time-dependently in the acute stage. Consistently, the present study also showed that WBC, ANC, CRP and ESR reached the largest values on day 10. In California, Tremoulet et al. [
25] performed a retrospective chart review of 380 KD patients and found that ANC and CRP peaked within the first 10 days of illness, whereas PLT peaked between day 11 and day 20. Lee et al. [
26] evaluated the inflammatory mediators according to the fever duration in 152 Korean children with KD and discovered that WBC, ANC and CRP reached their summits on day 6, earlier than our findings. Therefore, understanding the dynamic changes in laboratory parameters may assist pediatricians in evaluating the inflammatory status of KD patients.
The presence of fever for ≥5 days with 4 of the 5 other principal features fulfills the diagnosis of complete KD, whereas the above criteria unfortunately do not identify all children with the illness. According to the current available data, approximately 20 to 40% of patients are diagnosed with incomplete KD [
27,
28]. In this study, 45 patients developed incomplete KD (29.40%) and 27 of them (60.00%) received the initial IVIG dose on day 5 and 6. However, the clinical classification presented no significant heterogenicity among different treatment time, thus early recognition to incomplete KD seemed to be relatively challenging. Identically, Sittiwangkul et al. [
29] analyzed the medical records of 170 KD patients in Thailand from 2000 to 2008 and found that timing option of IVIG treatment was not associated with the onset of incomplete KD. In contrast, another clinical survey from Wenzhou [
7], China revealed that the proportion of incomplete KD in the delayed therapy group (received IVIG treatment > 10 days) was significantly higher than in the conventional therapy group (received IVIG treatment ≤10 days).
CAA serves as a predictor to the long-term prognosis of KD. Currently, several inflammatory mediators, such as NF-κB, interleukin (IL)-1β, IL-6, fibroblast growth factor-23 and transforming growth factor-β, have been reported to participate in CAA onset [
30‐
32]. Besides, a growing body of evidence have shown that SLC8A1, male, infants < 6 months old, low serum albumin, high ESR, CRP, mycoplasma infection, IVIG started after the 10th day of illness and IVIG non-responders may increase the risk of CAA [
33‐
35]. In the present study, the distribution of CAA onset was subjected to a significant difference according to timing option of IVIG treatment; a subsequent usage of IVIG may result in a higher occurrence of CAA and a more severe vasculitis requires more aggressive therapy. More persuasively, according to the 20th nationwide survey of KD in Japan [
36], CAA incidence during the convalescent phase was significantly higher in the late IVIG treatment group (≥10 days) than those who received IVIG treatment within day 10. Therefore, the early treatment of IVIG is considered to be effective for suppressing systemic inflammation and preventing CAA.
Acknowledgments
At the point of finishing this paper, I’d like to express my sincere thanks to all those who have lent me hands in the course of my writing this paper. We greatly appreciate PhD. Xun Xia, Dr. Bo Hu and Dr. Wei Wei for their helpful comments, Department of Pediatrics, the First Affiliated Hospital of Anhui Medical University, Hefei, China.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.